Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07391280

Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department

Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department — Recruiting • Non-phase study • Oncology • NCT07391280.

📅 01 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07391280
Sponsor
NHS Greater Glasgow and Clyde
Start
2026-05-25
ClinicaliQ Trial Snapshot
  • Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department — Recruiting • Non-phase study • Oncology • NCT07391280.
  • What is being tested: A computer programme designed to assist emergency department clinicians in earlier recognition and diagnosis of three major conditions—cancer, COPD, and heart failure—by analysing patient presentations and clinical data.
  • Patient eligibility overview: The study recruits adult patients presenting to the Emergency Department at Queen Elizabeth University Hospital; specific inclusion/exclusion criteria would be applied based on symptoms suggestive of cancer, COPD, or heart failure.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

SEARCH-ED is a research study which is running in Emergency Department (ED) of the Queen Elizabeth University Hospital. The aim of the study is to find out if using a computer programme can help doctors diagnose heart and lung problems from chest x-rays. We want to compare how many people are diagnosed with heart or lung problems for the first time when doctors have access to the computer programme results, in comparison to when they don't.

Eligibility Snapshot
  • : Unconsented Use of Harrison CXR Algorithm in Emergency Department (ED): * Frontal Chest X-Ray (CXR) (AP or PA) acquired in the Queen Elizabeth University Hospital (QEUH) ED * Patients aged 18 or over * Appropriate meta data (DICOM) to allow for Harrison CXR processing and secondary capture report provision. Patient Focus Groups: * Aged 18 or over * Able to provide written, informed consent in English. Clinician Focus Groups: * Aged 18 or over * Able to provide written, informed consent in English. * Working as a doctor, advanced nurse practitioner or advanced clinical practitioner in ED, radiology or downstream medical specialties * For post-implementation focus groups only, must have at least 4 months experience of working with Harrison CXR algorithm. Diagnostic Clinic: * Patients without terminal illness or advanced frailty * Usual healthcare provider based in NHS GGC

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Teen’s death inspires mum’s drive for earlier rare cancer diagnosis
Oncology · BBC Health · 16 Oct 2026
Soft tissue sarcomas in teenagers are being diagnosed late, prompting new diagnostic guidance to improve early recognition and outcomes Parents and clinicians…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
Wellbeing support demand for cancer patients grows
Oncology · BBC Health · 25 Oct 2026
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision may not meet patient…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Clinical Brief
‘Quick skin cancer pathway the best birthday gift’
Oncology · BBC Health · 09 Sep 2026
Key Takeaways for Clinical Practice Early referral through skin cancer fast-track pathways enables rapid diagnosis and treatment, improving outcomes for melanoma patients
View brief →